Please assess the completion status of the following clinical trial:

Trial Title: Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~INCLUSION CRITERIA FOR INITIAL STUDY ENROLLMENT:~Patients will be eligible for initial enrollment on this study as long as they meet the following criteria:~* Diagnosis of acute lymphoblastic leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, myelodysplastic syndrome, myeloproliferative disorder, Hodgkin lymphoma, non-Hodgkin lymphoma or non-malignant disease requiring allogeneic HSCT~* Birth to age 70 years of age~* Study entry consent is signed and faxed to Research Coordinator~INCLUSION CRITERIA AT TIME OF IL-2 ADMINISTRATION:~* At least day +7 post transplant~* Less than or equal to 30 days post transplant~* Lansky or Karnofsky score greater than or equal to 50%~* Total bilirubin less than or equal to 1.5mg/dL~* Alanine aminotransferase level (ALT) less than or equal to five times normal, serum direct bilirubin less than or equal to 1.5mg/dL, albumin greater than or equal to 3.0gm/dL~* Serum creatinine less than three times normal or creatinine clearance greater than 80mg/min/1.73m2~* Ensure that informed consent signed and faxed to Research Coordinator~EXCLUSION CRITERIA:~EXCLUSION CRITERIA AT TIME OF IL-2 ADMINISTRATION:~Patients will be ineligible to receive IL-2 injections if any of the following is true:~* Active, acute GVHD greater than or equal to grade II~* Serious, active bacterial, fungal or viral infection (i.e. intensive care)~* Clinical Signs of severe pulmonary dysfunction~* Clinical Signs of sever cardiac dysfunction~* Receiving corticosteroids as GVHD treatment~* Hypersensitivity or allergy to IL-2

- Gender: ALL
- Minimum Age: None
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- IL2 Administration (Type: EXPERIMENTAL): SCHEDULE OF IL-2 ADMINISTRATION: Patients will receive a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT.~Time will be measured as 'week beginning with first IL-2 injection.'~T cell Induction via IL-2 to reduce GVHD

Based on this trial design, predict the completion outcome and termination type (if applicable).